1. Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR

   • Li-Kuei Chen
   • Chien-Hung Shih
   • Kuen-Bao Chen

   Research 09 August 2022 Pages: 1165 - 1172

   

2. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine

   • Haiqin Ping
   • Wenjun Yu
   • Hengning Ke

   Research 13 August 2022 Pages: 1173 - 1184

   

3. Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer

   • Imene Ben Toumia
   • Marco Ponassi
   • Camillo Rosano

   Research 17 August 2022 Pages: 1185 - 1193

   

4. Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2^V617F and ASXL1 mutations

   • Jiajia Yuan
   • Junzhe Song
   • Yuan Zhou

   Research 31 August 2022 Pages: 1194 - 1205

   

5. Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics

   • Zhitao Ni
   • Shaolin Xu
   • Xiuhua Zhang

   Research 05 September 2022 Pages: 1206 - 1215

   

6. Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα

   • Zhiwei Chen
   • Xing Xia
   • Longfa Kou

   Research 07 September 2022 Pages: 1216 - 1230

   

7. Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia

   • Yanfeng Liu
   • Yan Jia
   • Mei Zhang

   Research 26 October 2022 Pages: 1231 - 1243

   

8. TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells’ killing

   • Xuejia Feng
   • Gui Yang
   • Qingxia Wu

   Research 28 October 2022 Pages: 1244 - 1253

   

9. Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer

   • Hayato Yokota
   • Kazuhiro Sato
   • Masatomo Miura

   Research 23 September 2022 Pages: 1254 - 1262

   

10. Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors

    • Emiliano Calvo
    • Cristiana Sessa
    • Alexander Drilon

    Research Open access 10 August 2022 Pages: 1263 - 1273

    

11. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects

    • Linlin Hu
    • Mingmin Cai
    • Huiping Wang

    Research 10 September 2022 Pages: 1274 - 1281

    

12. Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study

    • Peng Shen
    • Bo Qiao
    • Shuyan Wang

    Research 16 August 2022 Pages: 1282 - 1289

    

13. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

    • Nobuharu Tamaki
    • Toshifumi Tada
    • Namiki Izumi

    Research 24 September 2022 Pages: 1290 - 1297

    

14. Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer

    • Toshiyuki Sumi
    • Yuta Koshshino
    • Hirofumi Chiba

    Research 13 October 2022 Pages: 1298 - 1305

    

15. A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161

    • Lakshmi Rajdev
    • Ju-Whei Lee
    • Peter J. O’Dwyer

    Research 20 October 2022 Pages: 1306 - 1314

    

16. Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer

    • Toshiyuki Sumi
    • Motoki Sekikawa
    • Hirofumi Chiba

    Research 21 October 2022 Pages: 1315 - 1321

    

17. BMP2 as a promising anticancer approach: functions and molecular mechanisms

    • Tong-tong Li
    • Yong-wei Lai
    • Peng-xia Zhang

    Review 30 August 2022 Pages: 1322 - 1332

    

18. CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma

    • Bo Xu
    • Shaoqian Li
    • Jiecan Zhou

    Review 08 September 2022 Pages: 1333 - 1341

19. EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy

    • Shinsuke Ogusu
    • Ryo Ariyasu
    • Makoto Nishio

    SHORT REPORT 24 September 2022 Pages: 1342 - 1349

    

20. A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report

    • Chunguang Wang
    • Shu Chen
    • Peiran Xu

    Case Report 06 June 2022 Pages: 1350 - 1353

    

21. Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations

    • Shinichiro Okauchi
    • Hiroaki Satoh

    Correspondence 24 September 2022 Pages: 1354 - 1355

    

22. Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine

    • Haiqin Ping
    • Wenjun Yu
    • Hengning Ke

    Author Correction 27 August 2022 Pages: 1356 - 1356

23. Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report

    • Chunguang Wang
    • Shu Chen
    • Peiran Xu

    Publisher Correction 16 August 2022 Pages: 1357 - 1357